Our study also suggests that targeting either TPC‐EV‐derived Gas6 or the Axl pathway in EPCs can be a promising therapeutic strategy for enhancing the therapeutic efficacy of AA‐TKIs in CRC. Here, GAS6 is linked to colorectal carcinoma.